The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis

BMC Cancer

Research Article

Sung Hee Lim¹  Ji YunLee¹  Seung Tae Kim¹  Joon Oh Park¹  Min-Young Lee¹  Ho Yeong Lim¹  Young Suk Park¹  Jeeyun Lee¹  Hae Su Kim²  Seok Hyung Kim³  Yoon Ah Park⁴  Woo Yong Lee⁴  Woo Il Kwon⁴  Yong Beom Cho⁴  Jin Seok Heo⁴  Seong Hyeon Yun⁴  Hee Cheol Kim⁴  Yong Soo Choi⁵ 

[1] Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;Division of Hematology-Oncology, Department of Medicine, Veterans Health Service Medical Center, Seoul, Korea;Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

关键词: Colorectal cancer;    KRAS mutation;    Prognosis;    Metastases;   

DOI  :  10.1186/s12885-016-2141-4

 received in 2015-02-05, accepted in 2016-02-08,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundKRAS mutations are common in colorectal cancer (CRC). The role of KRAS mutation status as a prognostic factor remains controversial, and most large population-based cohorts usually consist of patients with non-metastatic CRC. We evaluated the impact of KRAS mutations on the time to recurrence (TTR) and overall survival (OS) in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy.MethodsPatients who underwent curative resection for primary and synchronous metastases were retrospectively collected in a single institution during a 6 year period between January 2008 and June 2014. Patients with positive surgical margins, those with known BRAF mutation, or those with an unknown KRAS mutation status were excluded, and a total of 82 cases were identified. The pathological and clinical features were evaluated. Patients’ outcome with KRAS mutation status for TTR and OS were investigated by univariate and multivariate analysis.ResultsKRAS mutations were identified in 37.8 % of the patients and not associated with TTR or OS between KRAS wild type and KRAS mutation cohorts (log-rank p = 0.425 for TTR; log-rank p = 0.137 for OS). When patients were further subdivided into three groups according to mutation subtype (wild-type vs. KRAS codon 12 mutation vs. KRAS codon 13 mutation) or amino acid missense mutation type (G > A vs. G > T vs. G > C), there were no significant differences in TTR or OS. Mutational frequencies were significantly higher in patients with lung metastases compared with those with liver and ovary/bladder metastases (p = 0.039), however, KRAS mutation status was not associated with an increased risk of relapsed in the lung.ConclusionsKRAS mutation was not associated with TTR or OS in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy.

【 授权许可】

CC BY   
© Kim et al. 2016